CN116284218A - Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance - Google Patents
Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance Download PDFInfo
- Publication number
- CN116284218A CN116284218A CN202310264615.4A CN202310264615A CN116284218A CN 116284218 A CN116284218 A CN 116284218A CN 202310264615 A CN202310264615 A CN 202310264615A CN 116284218 A CN116284218 A CN 116284218A
- Authority
- CN
- China
- Prior art keywords
- compound
- tag
- compounds
- dichloromethane
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 title claims abstract description 41
- 239000007791 liquid phase Substances 0.000 title claims abstract description 40
- 229940093441 palmitoyl oligopeptide Drugs 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000002194 synthesizing effect Effects 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 8
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 8
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 claims abstract description 6
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 claims abstract description 5
- 239000004471 Glycine Substances 0.000 claims abstract description 4
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 3
- 230000007017 scission Effects 0.000 claims abstract description 3
- 239000000969 carrier Substances 0.000 claims abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 144
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 75
- 239000007787 solid Substances 0.000 claims description 67
- 238000003756 stirring Methods 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 41
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 238000001308 synthesis method Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 15
- 239000012065 filter cake Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 12
- 239000012279 sodium borohydride Substances 0.000 claims description 12
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 10
- 229940125758 compound 15 Drugs 0.000 claims description 10
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 9
- 239000012295 chemical reaction liquid Substances 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229940126142 compound 16 Drugs 0.000 claims description 6
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 3
- 229940125797 compound 12 Drugs 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 239000002173 cutting fluid Substances 0.000 claims description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims 6
- 239000012530 fluid Substances 0.000 claims 3
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 17
- 238000003786 synthesis reaction Methods 0.000 abstract description 17
- 238000010511 deprotection reaction Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- -1 palmitoyl tripeptide-1 compound Chemical class 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229940126543 compound 14 Drugs 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 6
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 6
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- 229940126657 Compound 17 Drugs 0.000 description 6
- 238000011031 large-scale manufacturing process Methods 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- WSULSMOGMLRGKU-UHFFFAOYSA-N 1-bromooctadecane Chemical compound CCCCCCCCCCCCCCCCCCBr WSULSMOGMLRGKU-UHFFFAOYSA-N 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000004880 explosion Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- BDHUTRNYBGWPBL-HNNXBMFYSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-6-(phenylmethoxycarbonylamino)hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCNC(=O)OCC1=CC=CC=C1 BDHUTRNYBGWPBL-HNNXBMFYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- MDMNSAVSQAHVLC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group NCC(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 MDMNSAVSQAHVLC-MDTVQASCSA-N 0.000 description 1
- ITQQJWLUOAEZNS-UHFFFAOYSA-N 2-hydroxy-4-prop-2-enoxybenzaldehyde Chemical compound OC1=CC(OCC=C)=CC=C1C=O ITQQJWLUOAEZNS-UHFFFAOYSA-N 0.000 description 1
- RXNYJUSEXLAVNQ-UHFFFAOYSA-N 4,4'-Dihydroxybenzophenone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1 RXNYJUSEXLAVNQ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BLQSAXJSJHUEIQ-IBGZPJMESA-N benzyl (2s)-2-amino-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound C([C@H](N)C(=O)OCC=1C=CC=CC=1)CCCNC(=O)OCC1=CC=CC=C1 BLQSAXJSJHUEIQ-IBGZPJMESA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明属于药物合成技术领域,尤其涉及一种基于液相载体辅助合成棕榈酰三肽‑1的方法。先合成四种液相载体TAG‑A、TAG‑B,TAG‑C和TAG‑D,然后将其分别与Fmoc‑Lys(Boc)‑OH缩合得到化合物4A‑4D,脱保护后得到化合物5A‑5D;化合物5A‑5D再和Fmoc‑His(Trt)‑OH缩合得到化合物6A‑6D,脱保护得到化合物7A‑7D,化合物7A‑7D再和Fmoc保护的甘氨酸缩合得到化合物8A‑8D,脱保护得到化合物9A‑9D,化合物9A‑9D再和棕榈酸缩合得到全保护肽化合物10A‑10D;最后通过三氟乙酸裂解即可得到棕榈酰三肽‑1化合物。The invention belongs to the technical field of drug synthesis, in particular to a method for assisting synthesis of palmitoyl tripeptide-1 based on a liquid phase carrier. First synthesize four liquid phase carriers TAG-A, TAG-B, TAG-C and TAG-D, and then condense them with Fmoc-Lys(Boc)-OH to obtain compound 4A-4D, and obtain compound 5A-4D after deprotection 5D; compound 5A-5D was condensed with Fmoc-His(Trt)-OH to obtain compound 6A-6D, deprotected to obtain compound 7A-7D, compound 7A-7D was condensed with Fmoc-protected glycine to obtain compound 8A-8D, deprotected The compound 9A-9D was obtained, and the compound 9A-9D was condensed with palmitic acid to obtain the fully protected peptide compound 10A-10D; finally, the palmitoyl tripeptide-1 compound was obtained by cleavage with trifluoroacetic acid.
Description
技术领域technical field
本发明属于药物合成领域,尤其涉及一种基于液相载体辅助合成棕榈酰三肽-1的方法。The invention belongs to the field of drug synthesis, in particular to a method for assisting synthesis of palmitoyl tripeptide-1 based on a liquid phase carrier.
背景技术Background technique
棕榈酰三肽-1(英文名Pal-Tripeptide-1)由三个氨基酸和一个脂肪酸组成,氨基酸序列为甘氨酸-组氨酸-赖氨酸(GHK),将棕榈酸经酰化处理后可与GHK的N-端连接而形成目标肽。棕榈酰三肽-1是一种特殊的氨基酸多肽,作用于真皮层,可以使皮肤变得更加紧致,使皱纹变得舒缓,促进皮肤的新陈代谢,刺激细胞的增殖,可以达到去皱美白,对抗衰老,增加肌肤光泽的效果。Palmitoyl tripeptide-1 (English name Pal-Tripeptide-1) is composed of three amino acids and one fatty acid. The amino acid sequence is glycine-histidine-lysine (GHK). Palmitic acid can be combined with The N-terminals of GHK are linked to form the peptide of interest. Palmitoyl tripeptide-1 is a special amino acid polypeptide that acts on the dermis to make the skin firmer, relieve wrinkles, promote skin metabolism, stimulate cell proliferation, and achieve wrinkle removal and whitening. Anti-aging, increase skin radiance effect.
棕榈酰三肽-l的合成方法包括固相多肽合成和液相多肽合成两种方法,但是单纯采用固相法合成棕榈酰三肽-l由于肽序较短,固相载体昂贵,氨基酸用量大,而导致成本较高;液相合成法氨基酸用量小,收率高,但现有的液相合成法后处理工艺复杂,大量使用有机溶剂,成本偏高且不环保。The synthesis method of palmitoyl tripeptide-1 includes two methods of solid-phase peptide synthesis and liquid-phase peptide synthesis, but the synthesis of palmitoyl tripeptide-1 by the solid-phase method is relatively short, the solid phase carrier is expensive, and the amount of amino acids is large. , resulting in higher cost; the liquid-phase synthesis method uses less amino acid and has a high yield, but the existing liquid-phase synthesis method has a complex post-treatment process, a large amount of organic solvents are used, the cost is high and it is not environmentally friendly.
CN108218956A公开了一种棕榈酰三肽-1的液相合成方法。对棕榈酰三肽-1分段合成,分别合成了棕榈酰三肽-1序列中的二肽片段H-His-Lys(Z)-OBzl和另外一个片段Pal-Gly-OH,然后这两个片段以活化酯的方法合成了棕榈酰三肽的全保护肽,再通过氢化反应得到终产品棕榈酰三肽-1。在合成Pal-Gly-OH的时候,Pal-OH残留很难定量检测,该片段的合成需要根据另外一个片段合成情况来计算投料量,同时中间体Pal-Gly-ONb活性高不容易保存的问题也导致不容易进行大生产,且最后一步氢化通氢气容易有爆炸的风险,不适合进行大生产。CN108218956A discloses a liquid phase synthesis method of palmitoyl tripeptide-1. For the segmental synthesis of palmitoyl tripeptide-1, the dipeptide fragment H-His-Lys(Z)-OBzl and another fragment Pal-Gly-OH in the palmitoyl tripeptide-1 sequence were synthesized respectively, and then the two The fully protected peptide of palmitoyl tripeptide was synthesized by the method of activated ester, and then the final product palmitoyl tripeptide-1 was obtained through hydrogenation reaction. When synthesizing Pal-Gly-OH, the residue of Pal-OH is difficult to quantitatively detect. The synthesis of this fragment needs to calculate the dosage according to the synthesis of another fragment. At the same time, the intermediate Pal-Gly-ONb has high activity and is not easy to store. It also makes it difficult to carry out large-scale production, and the final step of hydrogenation and hydrogenation is likely to have the risk of explosion, which is not suitable for large-scale production.
CN112409444A和CN114891063A在公开的棕榈酰三肽-1的液相合成中都是先用Boc-Lys(Z)-OH和溴化苄反应,得到Boc-Lys(Z)-OBzl,再脱Boc得到H-Lys(Z)-OBzl;再与Boc-His-OH缩合后再脱Boc,得到H-His-Lys(Z)-OBzl;重复氨基酸偶联步骤,按照肽顺序依次偶联Boc-Gly-OH、Pal-OH,得Pal-Gly-His-Lys(z)-OBzl;最后氢化脱苄得到Pal-Gly-His-Lys-OH。该方法用到多种管制试剂不利于大规模生产,且最后一步氢化反应所用到的钯碳也非常危险,容易有着火和爆炸的风险,不适合进行大生产。CN112409444A and CN114891063A all use Boc-Lys(Z)-OH and benzyl bromide to react earlier in the liquid-phase synthesis of disclosed palmitoyl tripeptide-1 to obtain Boc-Lys(Z)-OBzl, and then remove Boc to obtain H -Lys(Z)-OBzl; then condense with Boc-His-OH and then remove Boc to obtain H-His-Lys(Z)-OBzl; repeat the amino acid coupling steps, and couple Boc-Gly-OH sequentially according to the peptide sequence , Pal-OH, to get Pal-Gly-His-Lys(z)-OBzl; finally hydrogenation debenzylation to get Pal-Gly-His-Lys-OH. This method uses a variety of controlled reagents, which is not conducive to large-scale production, and the palladium carbon used in the final hydrogenation reaction is also very dangerous, prone to fire and explosion risks, and is not suitable for large-scale production.
棕榈酰三肽-1的合成大都是采用了Boc保护氨基的策略进行的,先得到Boc-Lys(Z)-OBzl再与Boc-His-OH、Pal-Gly二肽缩合或者先接甘氨酸再接棕榈酸的方式得到棕榈酰三肽-1的全保护肽,最后再氢化脱苄得到榈酰三肽-1。但是在现有的合成路线中不难发现后处理纯化工艺是较为复杂的,所用溶剂的种类较多,溶剂量较大,且有部分溶剂属于管制溶剂,不利于规模化生产。在最后全保护肽脱保护的时候用到了钯碳和氢气,这在生产中也存在着安全隐患,会有爆炸和着火的风险。The synthesis of palmitoyl tripeptide-1 is mostly carried out by using the strategy of Boc to protect the amino group, first obtain Boc-Lys(Z)-OBzl and then condense with Boc-His-OH, Pal-Gly dipeptide or connect glycine first and then connect The fully protected peptide of palmitoyl tripeptide-1 was obtained by palmitic acid, and finally hydrogenated and debenzylated to obtain palmitoyl tripeptide-1. However, in the existing synthetic routes, it is not difficult to find that the post-treatment purification process is relatively complicated, and the types of solvents used are large, and the amount of solvents is large, and some solvents are regulated solvents, which is not conducive to large-scale production. In the final deprotection of the fully protected peptide, palladium carbon and hydrogen gas are used, which also has potential safety hazards in production, and there is a risk of explosion and fire.
近年来逐渐发展起来的液相载体技术很好的结合了固相多肽合成方法与传统液相多肽合成方法的优点,通过目标多肽的C端加装具有长疏水烷基链的保护基载体,每步反应都可以在卤代溶剂中进行,反应中间体可以用极性有机溶剂进行沉淀。与传统的液相多肽合成方法相比,后处理操作简单,每步中间体的纯度相对较高;与固相多肽合成方法相比,提高了氨基酸的利用率,节约了成本。但是,现有的液相载体辅助多肽药物的合成:①:可能会在脱保护步骤中产物有少许粘性,②:产品可能会在某些步骤的沉降过程中因为产物颗粒较细在过滤的操作中存在漏料的情况使产率降低。The liquid-phase carrier technology gradually developed in recent years combines the advantages of the solid-phase peptide synthesis method and the traditional liquid-phase peptide synthesis method. By adding a protective group carrier with a long hydrophobic alkyl chain to the C-terminus of the target polypeptide, each Each step reaction can be carried out in a halogenated solvent, and the reaction intermediate can be precipitated with a polar organic solvent. Compared with the traditional liquid-phase peptide synthesis method, the post-processing operation is simple, and the purity of the intermediate in each step is relatively high; compared with the solid-phase peptide synthesis method, the utilization rate of amino acids is improved and the cost is saved. However, the existing liquid phase carrier assists the synthesis of peptide drugs: ①: the product may have a little viscosity in the deprotection step, ②: the product may be difficult to filter during the sedimentation process of some steps because the product particles are fine The leakage of material in the production rate will be reduced.
发明内容Contents of the invention
本发明的目的是针对现有技术的不足,提供一种基于液相载体辅助合成棕榈酰三肽-1的方法。The purpose of the present invention is to provide a method for assisting the synthesis of palmitoyl tripeptide-1 based on a liquid phase carrier to address the deficiencies of the prior art.
本发明先用4,4-二羟基二苯甲酮(化合物1)作为原料,通过烷基化反应与1-溴十八烷反应得到化合物2,化合物2再被硼氢化钠还原得到疏水性液相载体化合物3(TAG-A)。The present invention first uses 4,4-dihydroxybenzophenone (compound 1) as a raw material, reacts with 1-bromooctadecane through an alkylation reaction to obtain compound 2, and then reduces compound 2 by sodium borohydride to obtain a hydrophobic liquid Phase carrier compound 3 (TAG-A).
其中,1-溴十八烷的用量在2.2当量-3当量之间;硼氢化钠的用量在1.0当量-3.0当量之间。Wherein, the amount of 1-bromooctadecane is between 2.2 equivalents and 3 equivalents; the amount of sodium borohydride is between 1.0 equivalents and 3.0 equivalents.
式1.液相载体合成路线一
式2.液相载体合成路线二Formula 2. Synthetic Route 2 of Liquid Phase Carrier
还可以用化合物14、化合物17或化合物19作为液相载体进行棕榈酰三肽-1的合成。Palmitoyl tripeptide-1 can also be synthesized by using compound 14, compound 17 or compound 19 as a liquid carrier.
化合物12先进行烷基化反应得到化合物13,化合物13再被硼氢化钠还原得到化合物14(TAG-B)。Compound 12 was alkylated first to obtain compound 13, which was then reduced by sodium borohydride to obtain compound 14 (TAG-B).
化合物14在二氯亚砜作用下得到化合物15,化合物15通过SN2反应得到化合物16,化合物16再被硼氢化钠还原得到化合物17(TAG-C)。Compound 14 was reacted with thionyl chloride to obtain compound 15, compound 15 was reacted by SN 2 to obtain compound 16, and compound 16 was reduced by sodium borohydride to obtain compound 17 (TAG-C).
此外,化合物15还可以通过SN2反应得到化合物18,化合物18再被硼氢化钠还原得到化合物19(TAG-D)。In addition, compound 15 can also be obtained by SN 2 reaction to obtain compound 18, which is then reduced by sodium borohydride to obtain compound 19 (TAG-D).
基于液相载体辅助合成棕榈酰三肽-1的方法为:液相载体TAG-A、TAG-B、TAG-C或TAG-D(化合物3/化合物14/化合物17/化合物19)与Fmoc-Lys(Boc)-OH缩合得到Fmoc-Lys(Boc)-TAG(化合物4A-4D),脱保护得到NH2-Lys(Boc)-TAG(化合物5A-5D);再和Fmoc-His(Trt)-OH缩合得到Fmoc-His(Trt)-Lys(Boc)-TAG(化合物6A-6D),脱保护得到NH2-His(Trt)-Lys(Boc)-TAG(化合物7A-7D),再和Fmoc保护的甘氨酸缩合得到Fmoc-Gly-His(Trt)-Lys(Boc)-TAG(化合物8A-8D),脱保护得到NH2-Gly-His(Trt)-Lys(Boc)-TAG(化合物9A-9D),再和棕榈酸缩合得到全保护肽Pal-Gly-His(Trt)-Lys(Boc)-TAG(化合物10A-10D)。最后通过三氟乙酸裂解即可得到棕榈酰三肽-1(化合物11)。The method for assisted synthesis of palmitoyl tripeptide-1 based on liquid phase carrier is: liquid phase carrier TAG-A, TAG-B, TAG-C or TAG-D (
式3.棕榈酰三肽-1合成路线
进一步的:化合物4A-4D的合成方法为:烧瓶中一次加入二氯甲烷、液相载体(TAG-OH)(化合物3/化合物14/化合物17/化合物19)、Fmoc-Lys(Boc)-OH(1.1当量-1.8当量)、N,N'-二异丙基碳二亚胺(1.1当量-1.8当量)、4-二甲氨基吡啶(0.1当量-0.6当量),搅拌3小时后,将二氯甲烷浓缩,冰浴下加入甲醇有固体析后继续搅拌10分钟,过滤,收集固体粉末化合物4A-4D。Further: the synthesis method of compound 4A-4D is: adding dichloromethane, liquid phase carrier (TAG-OH) (
化合物5A-5D的合成方法为:烧瓶中依次加入二氯甲烷、化合物4A-4D、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.0当量-2.5当量)室温搅拌30分钟后,将二氯甲烷浓缩,冰浴下加入乙腈有固体析出后继续搅拌10分钟,然后过滤,收集固体粉末化合物5A-5D。The synthetic method of compound 5A-5D is: add dichloromethane, compound 4A-4D, 1,8-diazobispiro[5.4.0] undec-7-ene (1.0 equivalent to 2.5 equivalent ) after stirring at room temperature for 30 minutes, dichloromethane was concentrated, acetonitrile was added under ice-cooling, and a solid precipitated, and the stirring was continued for 10 minutes, and then filtered to collect solid powder compounds 5A-5D.
化合物6A-6D的合成方法为:圆底烧瓶中依次加入二氯甲烷、Fmoc-His(Trt)-OH(1.1当量-1.8当量)、N,N-二异丙基乙胺(1.1当量-1.8当量)、N,N'-二异丙基碳二亚胺(1.1当量-1.8当量)、1-羟基苯并三唑、(1.1当量-1.8当量)搅拌10分钟后再将化合物5A-5D加入到反应液中继续搅拌3小时,然后将二氯甲烷浓缩,冰浴下加入甲醇有固体析出后继续搅拌10分钟,然后过滤,收集固体粉末6A-6D。The synthesis method of compound 6A-6D is: add dichloromethane, Fmoc-His(Trt)-OH (1.1 equivalents-1.8 equivalents), N,N-diisopropylethylamine (1.1 equivalents-1.8 eq), N,N'-diisopropylcarbodiimide (1.1 eq-1.8 eq), 1-hydroxybenzotriazole, (1.1 eq-1.8 eq), after stirring for 10 minutes, compound 5A-5D was added Stirring was continued for 3 hours in the reaction liquid, then dichloromethane was concentrated, methanol was added under ice-cooling, and solids were precipitated, and stirring was continued for 10 minutes, and then filtered to collect solid powders 6A-6D.
化合物7A-7D的合成方法为:圆底烧瓶中依次加入二氯甲烷、化合物6A-6D、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.0当量-2.5当量)室温搅拌30分钟后,将二氯甲烷浓缩,冰浴下加入乙腈有固体析出后来继续搅拌10分钟,然后过滤,收集固体粉末化合物7A-7D。The synthetic method of compound 7A-7D is: add dichloromethane, compound 6A-6D, 1,8-diazobispiro[5.4.0]undec-7-ene (1.0 equivalent- 2.5 equivalents) after stirring at room temperature for 30 minutes, dichloromethane was concentrated, acetonitrile was added under ice-cooling, and a solid was precipitated, then stirring was continued for 10 minutes, and then filtered to collect solid powder compounds 7A-7D.
化合物8A-8D的合成方法为:圆底烧瓶中依次加入二氯甲烷、Fmoc-Gly-OH(1.1当量-1.8当量)、N,N-二异丙基乙胺(1.1当量-1.8当量)、N,N'-二异丙基碳二亚胺(1.1当量-1.8当量)、1-羟基苯并三唑、(1.1当量-1.8当量)搅拌10分钟后再将化合物7A-7D加入到反应液中继续搅拌3小时,然后将二氯甲烷浓缩,冰浴下加入甲醇有固体析出后来继续搅拌10分钟,然后过滤,收集固体粉末化合物8A-8D。The synthesis method of compound 8A-8D is: add dichloromethane, Fmoc-Gly-OH (1.1 equivalents-1.8 equivalents), N,N-diisopropylethylamine (1.1 equivalents-1.8 equivalents), N,N'-diisopropylcarbodiimide (1.1-1.8 equivalents), 1-hydroxybenzotriazole, (1.1-1.8 equivalents) were stirred for 10 minutes and then compounds 7A-7D were added to the reaction solution Stirring was continued for 3 hours, then dichloromethane was concentrated, methanol was added under ice-cooling, and solids were precipitated, then stirring was continued for 10 minutes, and then filtered to collect solid powder compounds 8A-8D.
化合物9A-9D的合方法为:圆底烧瓶中依次加入二氯甲烷、化合物8A-8D、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.0当量-2.5当量)室温搅拌30分钟后,将二氯甲烷浓缩,冰浴下加入乙腈有固体析出后来继续搅拌10分钟,然后过滤,收集固体粉末化合物9A-9D。The synthesis method of compound 9A-9D is: add dichloromethane, compound 8A-8D, 1,8-diazobispiro[5.4.0]undec-7-ene (1.0 equivalent- 2.5 equivalents) after stirring at room temperature for 30 minutes, dichloromethane was concentrated, acetonitrile was added under ice-cooling, and a solid was precipitated, then stirring was continued for 10 minutes, and then filtered to collect solid powder compounds 9A-9D.
化合物10A-10D合成方法为:圆底烧瓶中依次加入二氯甲烷、棕榈酸(1.1当量-1.8当量)、N,N-二异丙基乙胺(1.1当量-1.8当量)、N,N'-二异基碳二亚胺(1.1当量-1.8当量)、1-羟基苯并三唑、(1.1当量-1.8当量)搅拌10分钟后再将化合物9A-9D加入到反应液中继续搅拌3小时,然后将二氯甲烷浓缩,冰浴下加入甲醇有固体析出后继续搅拌10分钟,过滤,收集固体粉末,30℃下真空干燥箱内烘干,得白色固体化合物10A-10D。The synthesis method of compound 10A-10D is as follows: add dichloromethane, palmitic acid (1.1 equivalent to 1.8 equivalent), N,N-diisopropylethylamine (1.1 equivalent to 1.8 equivalent), N,N' -Diisocarbodiimide (1.1 equivalents-1.8 equivalents), 1-hydroxybenzotriazole, (1.1 equivalents-1.8 equivalents) were stirred for 10 minutes and then compound 9A-9D was added to the reaction solution and continued to stir for 3 hours , then dichloromethane was concentrated, methanol was added under ice bath, and solid was precipitated, then stirred for 10 minutes, filtered to collect solid powder, and dried in a vacuum oven at 30°C to obtain white solid compounds 10A-10D.
棕榈酰三肽-1的合成方法为:圆底烧瓶中依次加入二氯甲烷、化合物10A-10D、待反应液溶清后加入切割液继续搅拌3小时,将反应液浓缩,0℃下加入异丙醚有固体析出后继续搅拌30分钟,然后过滤,收集滤饼,滤饼用100毫升水搅拌溶解后过滤,对滤液进行制备纯化,将收集液用冻干机冻干得白色固体最终产物棕榈酰三肽-1。The synthesis method of palmitoyl tripeptide-1 is as follows: add dichloromethane and compound 10A-10D in turn to the round bottom flask, add cutting solution after the reaction solution dissolves and continue to stir for 3 hours, concentrate the reaction solution, add iso Continue to stir for 30 minutes after the propyl ether has solid precipitation, then filter, collect the filter cake, stir and dissolve the filter cake with 100 ml of water and filter, prepare and purify the filtrate, and freeze-dry the collected solution to obtain the white solid final product palm Acyl tripeptide-1.
有益效果:Beneficial effect:
本发明利用液相载体合成棕榈酰三肽-1,用二氯甲烷做溶剂反应条件温和,后处理工艺简单,反应结束后可以通过大极性溶剂甲醇或者乙腈将产物沉淀出来,适合大规模生产。The present invention utilizes a liquid phase carrier to synthesize palmitoyl tripeptide-1, uses dichloromethane as a solvent, and has mild reaction conditions and simple post-treatment process. After the reaction, the product can be precipitated by a highly polar solvent, methanol or acetonitrile, and is suitable for large-scale production. .
本发明载体具有可溶性,反应为均相反应;提高了氨基酸的利用率,节约了成本。The carrier of the invention is soluble, and the reaction is a homogeneous reaction; the utilization rate of the amino acid is improved, and the cost is saved.
附图说明:Description of drawings:
图1:棕榈酰三肽-1的Ms图。Figure 1: Ms diagram of palmitoyl tripeptide-1.
具体实施方式Detailed ways
为使本发明的目的、技术方案及优点更加清楚明白,下面结合具体的实施方案对本发明作进一步解释,但是并不用于限制本发明的保护范围。In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention will be further explained below in conjunction with specific embodiments, but it is not intended to limit the protection scope of the present invention.
实施例1Example 1
25±5℃下,在500毫升圆底烧瓶中依次加入150毫升N,N-二甲基甲酰胺、化合物1(10克,46.68毫摩尔)、碳酸钾(14.2克,102.7毫摩尔)、1-溴十八烷(34.4克,102.7毫摩尔),然后90℃下反应4小时。反应结束后趁热倒入750毫升水中,25±5℃下搅拌30分钟后过滤,滤饼用500毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱中45℃下烘干,得白色固体化合物2 32.6克,收率97%。At 25±5°C, 150 ml of N,N-dimethylformamide, compound 1 (10 g, 46.68 mmol), potassium carbonate (14.2 g, 102.7 mmol), 1 -Bromooctadecane (34.4 g, 102.7 mmol), then reacted at 90° C. for 4 hours. After the reaction is completed, pour it into 750ml of water while it is still hot, stir at 25±5°C for 30 minutes and then filter, beat the filter cake with 500ml of methanol and filter, collect the white solid and dry it in a blast drying oven at 45°C to obtain a white solid Compound 2 32.6 g, yield 97%.
25±5℃下,在1升圆底烧瓶中依次加入350毫升四氢呋喃、化合物2、甲醇35毫升后加热60℃,待反应液溶清后加入硼氢化钠(1.7克,45毫摩尔)反应2小时。反应结束后待反应液降至室温后往反应液中缓慢滴加水,待反应液中无明显气泡产生时将反应液倒入2升水中搅拌30分钟后过滤,滤饼用500毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱45℃下烘干,得白色固体化合物3(TAG-A)31.3克,收率96%。At 25±5°C, add 350 ml of tetrahydrofuran, compound 2, and 35 ml of methanol to a 1-liter round-bottomed flask in sequence, then heat at 60°C, and add sodium borohydride (1.7 g, 45 mmol) after the reaction liquid is dissolved to react 2 Hour. After the reaction is finished, wait for the reaction solution to drop to room temperature, slowly add water dropwise to the reaction solution, and pour the reaction solution into 2 liters of water and stir for 30 minutes before filtering when there are no obvious bubbles in the reaction solution. The filter cake is beaten with 500 ml of methanol and then filtered. , collected the white solid and dried it in a forced air oven at 45° C. to obtain 31.3 g of white solid compound 3 (TAG-A), with a yield of 96%.
25±5℃下,在250毫升圆底烧瓶中依次加入50毫升二氯甲烷、化合物3(TAG-A,5克,6.93毫摩尔)、Fmoc-Lys(Boc)-OH(市售,成都郑源)(3.9克,8.32毫摩尔)、N,N'-二异丙基碳二亚胺(1.6毫升,10.4毫摩尔)、4-二甲氨基吡啶(169毫克,1.387毫摩尔)搅拌3小时后,将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升甲醇有固体析出来后继续搅拌10分钟。然后过滤,收集固体粉末化合物4A,抽干投下一步。At 25±5°C, add 50 ml of dichloromethane, compound 3 (TAG-A, 5 g, 6.93 mmol), Fmoc-Lys(Boc)-OH (commercially available, Zhengyuan, Chengdu) into a 250 ml round bottom flask. ) (3.9 g, 8.32 mmol), N,N'-diisopropylcarbodiimide (1.6 mL, 10.4 mmol), 4-dimethylaminopyridine (169 mg, 1.387 mmol) after stirring for 3 hours , dichloromethane was concentrated to about 5 milliliters, and 100 milliliters of methanol was added under ice-cooling, and the stirring was continued for 10 minutes after the solid precipitated out. Then filter, collect the solid powder compound 4A, drain it and put it into the next step.
25±5℃下,在250毫升圆底烧瓶中依次加入50毫升二氯甲烷、化合物4A、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.036毫升,6.93毫摩尔)室温搅拌30分钟后,将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升乙腈有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末化合物5A,抽干投下一步。At 25±5°C, add 50 ml of dichloromethane,
15±5℃下,在250毫升圆底烧瓶中依次加入50毫升二氯甲烷、Fmoc-His(Trt)-OH(5.157克,8.32毫摩尔)(市售,成都郑源)、N,N-二异丙基乙胺(1.56毫升,9毫摩尔)、N,N'-二异丙基碳二亚胺(1.6毫升,10.4毫摩尔)、1-羟基苯并三唑、(1.4克,10.4毫摩尔)搅拌10分钟后再将化合物5A加入到反应液中继续搅拌3小时。然后将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升甲醇有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末化合物6A,抽干投下一步。At 15±5°C, add 50 ml of dichloromethane, Fmoc-His(Trt)-OH (5.157 g, 8.32 mmol) (commercially available, Chengdu Zhengyuan), N,N-Di Isopropylethylamine (1.56ml, 9mmol), N,N'-diisopropylcarbodiimide (1.6ml, 10.4mmol), 1-hydroxybenzotriazole, (1.4g, 10.4mM mol) was stirred for 10 minutes, and then compound 5A was added into the reaction solution and stirred for 3 hours. Then dichloromethane was concentrated to about 5 milliliters, 100 milliliters of methanol was added under ice-cooling, solid was precipitated, and stirring was continued for 10 minutes. Then filter, collect the solid powder compound 6A, suck it dry and put it into the next step.
25±5℃下,在250毫升圆底烧瓶中依次加入50毫升二氯甲烷、化合物6A、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.036毫升,6.93毫摩尔)室温搅拌30分钟后,将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升乙腈有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末化合物7A,抽干投下一步。At 25±5°C, add 50 ml of dichloromethane,
20±5℃下,在250毫升圆底烧瓶中依次加入75毫升二氯甲烷、Fmoc-Gly-OH(2.47克,8.32毫摩尔)、N,N-二异丙基乙胺(1.56毫升,9毫摩尔)、N,N'-二异丙基碳二亚胺(1.6毫升,10.4毫摩尔)、1-羟基苯并三唑、(1.4克,10.4毫摩尔)搅拌10分钟后再将化合物7A加入到反应液中继续搅拌3小时。然后将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升甲醇有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末化合物8A,抽干投下一步。At 20±5°C, 75 ml of dichloromethane, Fmoc-Gly-OH (2.47 g, 8.32 mmol), N,N-diisopropylethylamine (1.56 ml, 9 mmol), N,N'-diisopropylcarbodiimide (1.6 ml, 10.4 mmol), 1-hydroxybenzotriazole, (1.4 g, 10.4 mmol) were stirred for 10 minutes and compound 7A Added to the reaction solution and continued to stir for 3 hours. Then dichloromethane was concentrated to about 5 milliliters, 100 milliliters of methanol was added under ice-cooling, solid was precipitated, and stirring was continued for 10 minutes. Then filter, collect the solid powder compound 8A, suck it dry and put it into the next step.
25±5℃下,在250毫升圆底烧瓶中依次加入50毫升二氯甲烷、化合物8A、1,8-二偶氮杂双螺环[5.4.0]十一-7-烯(1.036毫升,6.93毫摩尔)室温搅拌30分钟后,将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升乙腈有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末化合物9A,抽干投下一步。At 25±5°C, add 50 ml of dichloromethane,
20±5℃下,在250毫升圆底烧瓶中依次加入75毫升二氯甲烷、棕榈酸(2.13克,8.32毫摩尔)、N,N-二异丙基乙胺(1.56毫升,9毫摩尔)、N,N'-二异基碳二亚胺(1.6毫升,10.4毫摩尔)、1-羟基苯并三唑、(1.4克,10.4毫摩尔)搅拌10分钟后再将化合物9A加入到反应液中继续搅拌3小时。然后将二氯甲烷浓缩至5毫升左右,冰浴下加入100毫升甲醇有固体析出后来继续搅拌10分钟。然后过滤,收集固体粉末,30摄氏度下真空干燥箱内烘干,得白色固体化合物10A 10.55克,收率93.8%。At 20±5°C, add 75 ml of dichloromethane, palmitic acid (2.13 g, 8.32 mmol), N,N-diisopropylethylamine (1.56 ml, 9 mmol) in a 250 ml round bottom flask , N, N'-diisocarbodiimide (1.6 milliliters, 10.4 mmol), 1-hydroxybenzotriazole, (1.4 grams, 10.4 mmol) and then compound 9A was added to the reaction solution after stirring for 10 minutes Stirring was continued for 3 hours. Then dichloromethane was concentrated to about 5 milliliters, 100 milliliters of methanol was added under ice-cooling, solid was precipitated, and stirring was continued for 10 minutes. Then filter, collect the solid powder, and dry in a vacuum oven at 30°C to obtain 10.55 g of white solid compound 10A, with a yield of 93.8%.
10±5℃下,在500毫升圆底烧瓶中依次加入50毫升二氯甲烷、化合物10A、待反应液溶清后加入50毫升切割液(三氟乙酸:三异丙基硅烷:水=95:2.5:2.5)继续搅拌3小时。将反应液浓缩至20毫升左右,0℃下加入200毫升异丙醚有固体析出后继续搅拌30分钟。然后过滤,收集滤饼,滤饼用100毫升水搅拌溶解后过滤,对滤液进行制备纯化。将收集液用冻干机冻干得白色固体最终产物,收率62.5%,纯度>98%。At 10±5°C, add 50 ml of dichloromethane and compound 10A in sequence to a 500 ml round bottom flask, and add 50 ml of cutting fluid (trifluoroacetic acid: triisopropylsilane: water = 95: 2.5:2.5) Stirring was continued for 3 hours. The reaction solution was concentrated to about 20 ml, and 200 ml of isopropyl ether was added at 0° C., and a solid was precipitated, and the stirring was continued for 30 minutes. Then filter, collect filter cake, filter cake is stirred and dissolved with 100 milliliters of water after filtering, and filtrate is prepared and purified. The collected solution was lyophilized with a lyophilizer to obtain a white solid final product with a yield of 62.5% and a purity of >98%.
实施例2Example 2
25±5℃下,在500毫升圆底烧瓶中依次加入150毫升N,N-二甲基甲酰胺、化合物12(10克,72.46毫摩尔)、碳酸钾(30克,217毫摩尔)、1-溴十八烷(53.14克,159毫摩尔),然后90℃下反应4小时。反应结束后趁热倒入750毫升水中,25±5℃下搅拌30分钟后过滤,滤饼用500毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱中45℃下烘干,得白色固体化合物13 45.57克,收率98%。At 25±5°C, 150 ml of N,N-dimethylformamide, compound 12 (10 g, 72.46 mmol), potassium carbonate (30 g, 217 mmol), 1 -Bromooctadecane (53.14 g, 159 mmol), then reacted at 90° C. for 4 hours. After the reaction is completed, pour it into 750ml of water while it is still hot, stir at 25±5°C for 30 minutes and then filter, beat the filter cake with 500ml of methanol and filter, collect the white solid and dry it in a blast drying oven at 45°C to obtain a white solid Compound 13 45.57 g, yield 98%.
25±5℃下,在1升圆底烧瓶中依次加入400毫升四氢呋喃、化合物13、甲醇45毫升后加热60℃,待反应液溶清后加入硼氢化钠(2.68克,71毫摩尔)反应2小时。反应结束后待反应液降至室温后往反应液中缓慢滴加水,待反应液中无明显气泡产生时将反应液倒入2升水中搅拌30分钟后过滤,滤饼用500毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱45℃下烘干,得白色固体化合物14(TAG-B)45克,收率98%。At 25±5°C, add 400ml of tetrahydrofuran, compound 13, and 45ml of methanol to a 1-liter round-bottomed flask successively, then heat at 60°C, and add sodium borohydride (2.68g, 71mmol) after the reaction liquid is dissolved to react 2 Hour. After the reaction is finished, wait for the reaction solution to drop to room temperature, slowly add water dropwise to the reaction solution, and pour the reaction solution into 2 liters of water and stir for 30 minutes before filtering when there are no obvious bubbles in the reaction solution. The filter cake is beaten with 500 ml of methanol and then filtered. , collected the white solid and dried it in a forced air oven at 45° C. to obtain 45 g of white solid compound 14 (TAG-B), with a yield of 98%.
本发明基于液相载体辅助合成棕榈酰三肽-1的液相合成方法的一种实施例,除了使用的液相载体(本实施例使用化合物14(TAG-B))和实施例1不同之外,其他步骤和实施例1一致。最终可得到棕榈酰三肽-1的收率53%。An embodiment of the liquid-phase synthesis method of the present invention based on the liquid-phase carrier-assisted synthesis of palmitoyl tripeptide-1, except that the liquid-phase carrier used (compound 14 (TAG-B) is used in this example) is different from that of Example 1 Except, other steps are consistent with
实施例3Example 3
0±5℃下,在250毫升圆底烧瓶中依次加入100毫升二氯甲烷、化合物14、二氯亚砜1毫升后0℃反应1小时,反应结束后将反应液浓缩干再加100毫升二氯甲烷用5%碳酸氢钠水溶液洗一次,然后将二氯甲烷用无水硫酸镁干燥后浓缩干得到产物化合物15 4.8克,收率93%。At 0±5°C, add 100 ml of dichloromethane,
25±5℃下,在500毫升圆底烧瓶中依次加入80毫升N,N-二甲基甲酰胺、化合物15(4.8克,7.2毫摩尔)、碳酸钾(2克,14.5毫摩尔)、对羟基苯甲醛(1.06克,8.7毫摩尔),然后80℃下反应4小时。反应结束后趁热倒入500毫升水中,25±5℃下搅拌30分钟后过滤,滤饼用200毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱中45℃下烘干,得白色固体化合物16 5.1克,收率94%。At 25±5°C, 80 ml of N,N-dimethylformamide, compound 15 (4.8 g, 7.2 mmol), potassium carbonate (2 g, 14.5 mmol), and para Hydroxybenzaldehyde (1.06 g, 8.7 mmol) was then reacted at 80° C. for 4 hours. After the reaction is over, pour it into 500ml of water while it is hot, stir at 25±5°C for 30 minutes and then filter, beat the filter cake with 200ml of methanol and filter, collect the white solid and dry it in a blast drying oven at 45°C to obtain a white solid Compound 16 5.1 g, yield 94%.
25±5℃下,在250毫升圆底烧瓶中依次加入45毫升四氢呋喃、化合物16、甲醇5毫升后加热60℃,待反应液溶清后加入硼氢化钠(0.26克,6.8毫摩尔)反应2小时。反应结束后待反应液降至室温后往反应液中缓慢滴加水,待反应液中无明显气泡产生时将反应液倒入300毫升水中搅拌30分钟后过滤,滤饼用100毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱45℃下烘干,得白色固体化合物17(TAG-C)4.9克,收率96%。At 25±5°C, add 45 ml of tetrahydrofuran, compound 16, and 5 ml of methanol to a 250 ml round-bottomed flask successively, then heat at 60°C, and add sodium borohydride (0.26 g, 6.8 mmol) after the reaction liquid is dissolved to react 2 Hour. After the reaction is finished, wait for the reaction solution to drop to room temperature, and slowly add water dropwise to the reaction solution. When there are no obvious bubbles in the reaction solution, pour the reaction solution into 300 ml of water and stir for 30 minutes before filtering. The filter cake is beaten with 100 ml of methanol and then filtered. , collected the white solid and dried it in a forced air oven at 45° C. to obtain 4.9 g of white solid compound 17 (TAG-C), with a yield of 96%.
本发明基于液相载体辅助合成棕榈酰三肽-1的液相合成方法的一种实施例,除了使用的液相载体和实施例1(本实施例使用化合物17(TAG-C))不同之外,其他步骤和实施例1一致。最终可得到棕榈酰三肽-1的收率65%。An embodiment of the liquid-phase synthesis method of the present invention based on liquid-phase carrier-assisted synthesis of palmitoyl tripeptide-1, except that the liquid-phase carrier used is different from Example 1 (compound 17 (TAG-C) is used in this example) Except, other steps are consistent with
实施例4Example 4
25±5℃下,在500毫升圆底烧瓶中依次加入80毫升N,N-二甲基甲酰胺、化合物15(4.8克,7.2毫摩尔)、碳酸钾(2克,14.5毫摩尔)、4-(烯丙氧基)-2-羟基苯甲醛(1.54克,8.7毫摩尔),然后80℃下反应4小时。反应结束后趁热倒入500毫升水中,25±5℃下搅拌30分钟后过滤,滤饼用200毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱中45℃下烘干,得白色固体化合物18 5.3克,收率91%。At 25±5°C, 80 ml of N,N-dimethylformamide, compound 15 (4.8 g, 7.2 mmol), potassium carbonate (2 g, 14.5 mmol), 4 -(allyloxy)-2-hydroxybenzaldehyde (1.54 g, 8.7 mmol), then reacted at 80°C for 4 hours. After the reaction is over, pour it into 500ml of water while it is hot, stir at 25±5°C for 30 minutes and then filter, beat the filter cake with 200ml of methanol and filter, collect the white solid and dry it in a blast drying oven at 45°C to obtain a white solid Compound 18 5.3 g, yield 91%.
25±5℃下,在250毫升圆底烧瓶中依次加入45毫升四氢呋喃、化合物18、甲醇5毫升后加热60℃,待反应液溶清后加入硼氢化钠(0.25克,6.6毫摩尔)反应2小时。反应结束后待反应液降至室温后往反应液中缓慢滴加水,待反应液中无明显气泡产生时将反应液倒入300毫升水中搅拌30分钟后过滤,滤饼用100毫升甲醇打浆后过滤,收集白色固体在鼓风干燥箱45℃下烘干,得白色固体化合物19(TAG-D)4.7克,收率88%。At 25±5°C, add 45 ml of tetrahydrofuran, compound 18, and 5 ml of methanol to a 250 ml round-bottomed flask in sequence, then heat to 60°C, and add sodium borohydride (0.25 g, 6.6 mmol) after the reaction liquid is dissolved to react 2 Hour. After the reaction is finished, wait for the reaction solution to drop to room temperature, and slowly add water dropwise to the reaction solution. When there are no obvious bubbles in the reaction solution, pour the reaction solution into 300 ml of water and stir for 30 minutes before filtering. The filter cake is beaten with 100 ml of methanol and then filtered. , collected the white solid and dried it in a forced air oven at 45° C. to obtain 4.7 g of white solid compound 19 (TAG-D), with a yield of 88%.
本发明基于液相载体辅助合成棕榈酰三肽-1的液相合成方法的一种实施例,除了使用的液相载体和实施例2(本实施例使用化合物19(TAG-D))不同之外,其他步骤和实施例2一致。最终可得到棕榈酰三肽-1的收率63%。An embodiment of the liquid-phase synthesis method of the present invention based on the liquid-phase carrier-assisted synthesis of palmitoyl tripeptide-1, except that the liquid-phase carrier used is different from that of Example 2 (compound 19 (TAG-D) is used in this embodiment) Except, other steps are consistent with embodiment 2. Finally, the yield of palmitoyl tripeptide-1 was 63%.
以上实施例仅用以说明本发明的技术方案,其描述较为具体和详细,而非对其限制。对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出各种更改和变化,这些都属于本发明的保护范围。The above embodiments are only used to illustrate the technical solution of the present invention, and the description thereof is specific and detailed, but not limiting. For those skilled in the art, various modifications and changes can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310264615.4A CN116284218A (en) | 2023-03-17 | 2023-03-17 | Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310264615.4A CN116284218A (en) | 2023-03-17 | 2023-03-17 | Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116284218A true CN116284218A (en) | 2023-06-23 |
Family
ID=86784754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310264615.4A Pending CN116284218A (en) | 2023-03-17 | 2023-03-17 | Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116284218A (en) |
-
2023
- 2023-03-17 CN CN202310264615.4A patent/CN116284218A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109836455B (en) | Liquid phase synthesis method of thymopentin based on phosphorus or phosphorus acyloxy diphenyl methanol and derivatives thereof and assistance | |
CN101357937B (en) | Method for synthesizing atosiban acetate from solid phase polypeptide | |
CN107936108A (en) | A kind of liquid phase synthesis method of snake venom tripeptide | |
CN110684077A (en) | A kind of large-scale synthesis method of ajirelin | |
CN111732628A (en) | A kind of synthetic method of GHK tripeptide | |
CN107056894B (en) | Method for solid-phase synthesis of ganirelix acetate by fragment method | |
CN111732649B (en) | Preparation of liraglutide by continuous flow solid phase reaction | |
CN110128505A (en) | A kind of synthetic method of Goserelin impurity | |
CN116425827A (en) | Short peptide Fmoc-L-Ile-Aib-OH and preparation method thereof | |
CN113667007A (en) | Liquid-phase preparation method of side chain of Somaloutide | |
CN116284218A (en) | Method for synthesizing palmitoyl tripeptide-1 based on liquid phase carrier assistance | |
CN111690037A (en) | Method for synthesizing GHK acetate | |
CN114213503A (en) | Synthesis method of snake venom-like tripeptide | |
WO2021103458A1 (en) | Solid-phase synthesis method for degarelix | |
CN110317130B (en) | Compound and preparation method and application thereof | |
CN116239513B (en) | The preparation method of the key intermediate of MMAE, the preparation method of MMAE and antibody-conjugated drug | |
CN102336813B (en) | A kind of preparation method of synthesizing proteidin with solid phase polypeptide | |
CN113045641B (en) | A preparation method of semaglutide | |
CN113024637B (en) | Method for preparing carfilzomib by taking water-soluble alkynylamide as condensing agent | |
CN111285921B (en) | BDK auxiliary group and liquid phase total synthesis method of procalcitonin and analog based on BDK auxiliary group | |
CN116284238A (en) | Method for synthesizing polypeptide medicine | |
CN111393508B (en) | Preparation method of atosiban | |
CN117209540B (en) | Hexa (X-phenoxy) cyclotriphosphazene compound, preparation method and application in preparation of tetrapeptide gastrin | |
CN112521482A (en) | Preparation method for synthesizing nesiritide by solid-liquid combination | |
CN117003791B (en) | Diphenylphosphinoyloxy bisphenol A compound and application thereof in preparation of whitening nonapeptide-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |